OTC Bulletin Board S & P Company Insight for WAFERGEN BIO-SYSTEMS
Profile
	Business Summary: WaferGen Biosystems, Inc., a development stage company, engages in the development, manufacture, and sale of systems for gene expression, genotyping, and stem cell research for the life sciences, pharmaceutical drug discovery, and biomarker discovery and diagnostic products industries.   Address   Bayside Technology Center   46531 Fremont Blvd.   Fremont , CA 94538   Phone: 510-651-4450   Website: http://www.wafergen.com Auditor   George Stewart   Reno Transfer Agent   Continental Stock Transfer & Trust Co. Employees:  23 ShareHolders:  102 Founded:  2005 Domicile:  Nevada
Background
	WaferGen Biosystems, Inc., a development stage company, engages in the development, manufacture, and sale of systems for gene expression, genotyping, and stem cell research for the life sciences, pharmaceutical drug discovery, and biomarker discovery and diagnostic products industries. It offers SmartSlide Micro-Incubation system that provides a controlled environment and physiological conditions for imaging studies, allowing researchers to characterize, differentiate, and proliferate various cells, as well as provides growth conditions for stem and primary cells. The company also develops the SmartChip Real Time PCR System, which allows identification of the expressed genes. WaferGen offers its products for professionals performing genetic analysis and cell biology at pharmaceutical and biotech companies, academic and private research centers, and diagnostics companies involved in biomarker research. The company was founded in 2002 and is based in Fremont, California. History:  INCORPORATED in Nevada Aug. 4, 2005, as Scuttlebutt Yachts, Inc.; name changed to La Burbuja Cafe, Inc. June 20, 2006, and to WaferGen Bio-systems, Inc. Jan. 31, 2007. On May 31, 2007, the company acquired WaferGen, Inc., a Delaware corporation (WaferGen), through merger of a wholly owned subsidiary of the company into WaferGen. In the merger, 8,214,523 Common shares were issued to holders of WaferGen's Common stock. In addition, the company transferred all of its pre-merger operating assets and liabilities to a wholly owned subsidiary, La Burbuja Leaseco, Inc.; and it transferred all of the outstanding capital stock of that subsidiary to a major stockholder in exchange for cancellation of 4,277,778 Common shares of the company held by such stockholder.   Subsidiaries: WaferGen, Inc.
Management
	Management Officers Position  Alnoor  Shivji Chairman, President & Chief Executive Officer  Amjad  Huda Treasurer, Chief Financial Officer & Investor Relations Contact  Mona  Chadha Chief Operating Officer  Victor  Joseph Secretary & Chief Technology Officer  David H. Gelfand Chief Scientific Officer  Sharat  Singh SR VP Directors  Raymond Dean Hautamaki  Amjad  Huda  Victor  Joseph  Makoto  Kaneshiro  Joel S. Kanter  Alnoor  Shivji
Annual Report
	Annual Report   Income Statement   2007 2007 2006 Revenues $228,973 $294,268 $50,495 Cost of sales 79,116 100,866 14,750 Gross margin 149,857 193,402 35,745 Operating expenses: Sales and marketing 848,818 1,001,223 152,405 Research and development 2,429,273 6,068,128 1,624,237 General and administrative 2,802,938 4,786,974 945,554 Total operating expenses 6,081,029 11,856,325 2,722,196 Operating loss (5,931,172) (11,662,923) (2,686,451) Other income and (expenses): Interest income 163,047 163,047 ---------- Interest expense (189,539) (297,033) ---------- Total other income and (expenses) (26,492) (133,986) ---------- Net loss before provision for income taxes (5,957,664) (11,796,909) (2,686,451) Provision for income taxes ---------- -------------- ---------- Net loss (5,957,664) (11,796,909) (2,686,451) Accretion on Series B Preferred Stock (51,998) (155,998) (104,000) Net loss applicable to common stockholders $(6,009,662) $(11,952,907) $(2,790,451) Net loss per share - basic and diluted $(0.40) $(0.81) Shares used to compute net loss per share - basic and diluted $15,119,255 $3,448,260 Operating Income As Calculated Depr. and Amort. Fixed Charges Coverage: Available for Fixed Charges Gross Fixed Charges Fixed Charges Times Earnings Fixed Charges Coverages and Preferred Dividends Times Earnings Capital Expenditures Research & Development Expenditures   Balance Sheet   2007 Assets Current assets: Cash and cash equivalents $5,189,858 Accounts receivables 139,827 Inventories 62,521 Prepaid expenses and other current assets 87,487 Total current assets 5,479,693 Property and equipment, net 321,159 Other assets 54,016 Total assets $5,854,868 Liabilities, Series B Preferred Stock, and Stockholders ' Equity (Deficit) Current liabilities: Accounts payable $560,641 Accrued rent 19,340 Accrued payroll 414,519 Accrued vacation 156,234 Current portion of capital lease obligations 32,443 Total current liabilities 1,183,177 Capital lease obligations, net of current portion 73,451 Commitment and contingencies ----------- Stockholders' equity (deficit): Preferred Stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding ----------- Common Stock: $0.001 par value; 300,000,000 shares authorized; 23,217,846 shares issued and outstanding at December 31, 2007 23,218 Additional paid-in capital 16,527,929 Accumulated deficit (11,952,907) Total stockholders' equity (deficit) 4,598,240 Total liabilities, Series B Preferred Stock, and stockholders' equity (deficit) $5,854,868 Net Working Capital Equity per Share Depr. and Amort. Reserve Preferred Shares Issued Common Shares Issued Treasury Shares - Preferred Treasury Shares - Common
Interim Report
	Interim Report      Data Not Available
Pro Forma Report
	Pro Forma Report      Data Not Available
Quarterly Report
	Quarterly Report Information      Quarterly Revenue, US$ Year Quarter Revenue   2008   1 180,000   2008   2 180,000   2008   3 200,000   2008   4 70,000   2008   Full Year 620,000   2007   1 60,000   2007   3 10,000   2007   4 160,000   2007   Full Year 230,000   2006   1 10,000   2006   3 30,000   2006   4 10,000   2006   Full Year 50,000     Quarterly Net Income, US$ Year Quarter Revenue   2008   1 (1,890,000)   2008   2 (2,140,000)   2008   3 (2,070,000)   2008   4 (1,940,000)   2008   Full Year (8,040,000)   2007   3 (1,690,000)   2007   4 (2,270,000)   2007   Full Year (5,960,000)   2006   Full Year (2,690,000)   2005   Full Year (1,490,000)     Quarterly EPS, US$ Year Quarter Revenue   2008   1 (.08)   2008   2 (.09)   2008   3 (.08)   2008   4 (.08)   2008   Full Year (.33)   2007   1 (.04)   2007   2 (.10)   2007   3 (.07)   2007   4 (.10)   2007   Full Year (.40)   2006   2 (.04)   2006   3 (.03)   2006   4 (.11)   2006   Full Year (.47)   2005   Full Year (.06)
Stock Data
	Capitalization as of 09/30/2008:     Authorized Shares Outstanding Shares Preferred $0.001 par 10,000,000 None Common $0.001 par 300,000,000 24,830,932   LONG TERM DEBT: $38,612.   Common $0.001 par   Stockholders:  03/25/2008, 102. PRINCIPAL STOCKHOLDERS: March 31, 2008, Alnoor Shivji and a related trust owned or controlled 16.5% of the Common, YA Global Investments, LP 7.3%, CSK-VC Life Science Investment Fund LP 7.3% and The Shivji Family Trust dtd June 12, 2000 7.2%.   Transfer Agent:  Continental Stock Transfer & Trust Co.   New York , NY   OTC Bulletin Board( Primary): WGBS   Exchange Year High Low OTC Bulletin Board 2008 2.9000 0.5600 OTC Bulletin Board 2007 2.6000 1.0600   DIVIDENDS: Common $0.001 par: No cash. Common split 3.8888889-for-1, Mar. 6, 2007.